PolyPid PYPD 深 滬
等待開盤 09-04 09:30:00 美东时间
3.42
+0.010
+0.29%
華盛通- 最 高3.52
- 今 開3.42
- 成交量 17.54万股
- 最 低 3.35
- 昨 收 3.41
- 總市值 3485.29万
- 52周最高 3.93
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 2.30
- 委 比 13.04%
- 總股本 1019.09万
- 歷史最高 583.50
- 量 比 3.76
- 振 幅 4.99%
- 歷史最低 2.30
- 每 手 1
- 風險率 0.35%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多PolyPid to Participate in the Upcoming 27th Annual H.C. Wainwright Global Investment Conference
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company focused on improving surgical outcomes, announced that its senior management will participate in the 27th Annual H.C. Wainwright Global Investment Conference on September 8-9, 2025. The company will host a fireside chat with H.C. Wainwright Managing Director Brandon Folkes on September 8, alongside virtual and in-person investor meetings. PolyPid specializes in controlled drug delivery u...
09-03 12:30
PolyPid to Present at the 14th Meeting of the Israel Controlled Release Society Conference
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma company, announced that Dalit Hazan, its Deputy CEO and EVP of R&D, Clinical, and Regulatory Affairs, will present on "Novel Local Prolonged Drug Delivery: From Platform Idea to a Successful Phase III Trial" at the 14th Israel Controlled Release Society (ICRS) Conference on September 7-9, 2025. The presentation, scheduled for September 7, 2025, from 5:25 PM to 5:45 PM local time, will focus on a...
09-02 12:30
美股大行评级 | 潜在涨幅仍有782.74%！Passage BIO遭Canaccord Genuity下调目标价至67美元，维持"买入"评级
今日重点评级关注：Northland Capital Markets：维持BrainsWay"跑赢大市"评级，目标价从15美元升至19美元；Lake Street：维持Hyperfine"买入"评级，目标价从1.5美元升至2美元
08-15 09:30
美股大行评级 | 潜在涨幅95.33%！HC Wainwright & Co.上调Insmed目标价至240美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Insmed"买入"评级，目标价从120美元升至240美元；巴克莱：维持Transocean"超配"评级，目标价从3.5美元升至4美元
08-14 09:25
HC Wainwright & Co. Reiterates Buy on PolyPid, Maintains $13 Price Target
HC Wainwright & Co. analyst Brandon Folkes reiterates PolyPid (NASDAQ:PYPD) with a Buy and maintains $13 price target.
08-14 01:40
PolyPid Reports Positive Phase 3 Results and Strengthens Leadership
An announcement from PolyPid ( ($PYPD) ) is now available. On August 11, 2025, ...
08-13 19:57
PolyPid GAAP EPS of -$0.78
PolyPid press release (NASDAQ:PYPD): Q2 GAAP EPS of -$0.78. As of June 30, 2025, the company had cash and cash equivalents and short-term deposits in the amount of $29.5 million, compared to $15.6 mil...
08-13 19:39
PolyPid Q2 EPS $(0.78) Misses $(0.55) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.78) per share which missed the analyst consensus estimate of $(0.55) by 42.6 percent. This is a 37.6 percent increase over losses of $(1.25) per share from the same
08-13 19:33
Earnings Scheduled For August 13, 2025
Companies Reporting Before The Bell • Evotec (NASDAQ:EVO) is projected to repor...
08-13 16:32
PolyPid appoints Nurit Tweezer-Zaks as chief medical officer
PolyPid (NASDAQ:PYPD) announced on Tuesday the appointment of Dr. Nurit Tweezer-Zaks as chief medical officer, effective as of August 18, 2025. Tweezer-Zaks, who has served on PolyPid's board of dire...
08-12 21:05
